


5-hydroxytryptamine

5-hydroxytryptamine

2000 6



가

.

,

,

,

.

,

,

.

가

.

.

.....	1
.....	4
.....	8
1.	8
가.	8
.....	8
2.	9
가.	9
가 9	9
fluoxetine	10
5-HT 5-HIAA 	10
3.	13
.....	14
1.	14
2. SCL-90 HDS	15
가. SCL-90 HDS 	15
..... SCL-90	
HDS	15

3.		PRP 5-HT	PPP 5-HAA	
	, 5-HT		 17
	가.		5-HT 5-HAA	
			 17
	.		5-HT	
		5-HAA	 17
	.		5-HT 5-HAA	
			 17
4.		5-HT	, 5-HAA	
			 18
	가.	PRP 5-HT	SCL-90 HDS 18
	.	PPP 5-HT	SCL-90 HDS 19
	.	5-HT	SCL-90 HDS 19
	.	PPP 5-HAA	SCL-90 HDS 19
5.		5-HT	5-HAA	. 21
	가.	PRP 5-HT	SCL-90 HDS 21
	.	PPP 5-HT	SCL-90 HDS 21
	.	5-HT	SCL-90 HDS 21
	.	PPP 5-HAA	SCL-90 HDS 21
 23
 32
			 34
			 43

1.		14
2.		,	
	SCL-90	HDS 16
3.		,	
	5-HT	5-HIAA 18
4.		5-HT	
		20
5.	5-HT	 22

5-hydroxytryptamine

(noradrenaline) (5-hydroxy-tryptamine, 5-HT)

(selective serotonin reuptake inhibitor, SSRI) 5-HT

5-HT

5-HT

5-HT 5-hydroxyindoleacetic acid (5-HIAA)

5-HT (PRP 5-HT),

5-HT (PPP 5-HT),

5-HT (PPP 5-HIAA)) 가 . 4

SSRI PRP 5-HT , PPP 5-HT , 5-HT ,

PPP 5-HIAA

가

31 , 21

(symptom check list, SCL-90) Hamilton depression scale(HDS) . 5-HT 5-HIAA high performance liquid chromatography(HPLC)

PRP 5-HT, PPP 5-HT,

5-HT , PPP 5-HIAA

paired t-test

Pearson's correlation

test

1. SCL-90

HDS

PRP 5-HT , PPP 5-HT , 5-HT , PPP 5-HIAA

2. SCL-90

HDS

, PRP

5-HT , PPP 5-HT , 5-HT

3. PRP 5-HT 5-HT

SCL-90 HDS

가

SCL-90

-

가

PPP 5-HT

PPP 5-HIAA

가 .

4. PRP 5-HT , PPP 5-HT , PPP 5-HIAA

SCL-90 HDS

, 5-HT HDS

가 .

, PRP 5-HT , PPP 5-HT

5-HT

-

5-HT SSRI

가 , 5-HT (transporting

system)

가

,

.

: , , 5-HT

5-hydroxytryptamine

I.

20 (serotonin, 5-hydroxytryptamine, 5-HT) 가 .
(selective serotonin reuptake inhibitor, SSRI)가 5-HT가 가 가 ¹⁻³ .
5-HT , ,
^{4, 5} 5-HT 가
⁶ , ^{7, 8} .
5-HT
1) (tryptophan) , 2) 5-hydroxyindoleac-

etic acid(5-HIAA) , 3) 5-HT₂

가, 4) 5-HT (transporter binding) , 5)

5-HT , 6) fenfluramine (prolactin)

.^{9, 10} 5-HT

가 ,^{11, 12} 5-HT

.^{13, 14} L-tryptophan fenfluramine

5-HT challenge test prolactin

¹⁵ 5-HT 5-HIAA가 ,¹⁶

5-HIAA

.¹⁶⁻¹⁹ 5-HT

5-HT 5-HIAA

가

.²⁰⁻²⁴

SSRI

, , (1)

가

가 .²⁵⁻²⁷ 5-HT 가

²⁸

30% ,


(serotonergic agonist)

. 5-HT

. 5-HT

(postsynaptic receptors)

(down-regulation)



5-HT 5-HIAA

5-HIAA ⁴⁰

5-HIAA ⁴¹

가

5-HT 5-HIAA SSRI 5-HT, 5-HIAA

1)

5-HT (PRP 5-HT)

5-HT (PPP 5-HT) 5-HIAA (

PPP 5-HIAA) 5-HT (

5-HT)

2) PRP 5-HT , PPP 5-HT , 5-HT PPP

5-HIAA 가 가

3) SSRI PPP 5-HT , PRP 5-HT , 5-HT

PPP 5-HIAA

II.

1.

가.

. DSM IV 42
,
18 60 , 2
,
,
, 2
, 가
, , , ,
,
2
,
(informed consent) .

2.

가.

DSM IV

2

가

가

가

SCL-90⁴³

가

SCL-90

90

5

,

“

”, “

”, “

”, “

”, “

”,

0

4

90

가

83

9

7

. 9

T1

(somatization), T2

(obsessive-compulsive), T3

(interpersonal-sensitivity),

T4 (depression), T5

(anxiety), T6

(hostility)

T7 (phobic anxiety), T8

(paranoid ideation),

T9 (psychotism)

Hamilton depression rating scale⁴⁴ 24

1960 Max Hamilton

가

가

가 interrater reliability

Pearson's product-moment correlation coefficient

r=0.85

(p<0.01)

가

. fluoxetine

1 fluoxetine 20mg

⁴⁵ 1 20mg

4

benzodiazepine

(halcion)

5-HT 5-HIAA

(1) : 5-HT 가
가^{46,47}

5-HT tryptophan

2

Diurnal variation

9 10

5cc sodium citrate tube 1,200

rpm 3 (platelet rich plasma)

2,500 rpm 10

pellet (platelet poor plasma)

pellet

()

-70

(2) 5-HT 5-HIAA : 5-HT

(electrochemical detector)가 high performance

liquid chromatography(HPLC)

.⁴⁸

(가) HPLC : HPLC Waters (Waters Associates, Milford, MA, USA) model 510 pump, model 717 plus autosampler, model M60 amperometric detector . column Shiseido (Tokyo, Japan) 150 ×4.6mm I.D, 5mm particle size, reversed phase C₈ column column temperature 32 . Hewlett-Packard 3396 recording integrator (Palo Alto, CA, U.S.A.) chromatography

() : , sodium acetate, citric acid, EDTA(ethylene diamine tetra-acetic acid), sodium octane sulfonic acid, n-w-nethyl-5-hydroxytryptamine(NMET), 5-HIAA, 5-HT Sigma (St. Louis, MO, USA), nethyl alcohol Burdick and Jackson (Muskegon, M, USA), lyophilized serum Bio-Rad (Segrate, Italy), perchloric acid Wako (Osaka, Japan), glacial acetic acid Yakuri (Osaka, Japan) . Milli-Q water purification system(Millipore Corp, Bedford, MA, USA) 3

. stock 1 ng/ml -70 가

() 5-HT 5-HIAA :

5-HT 5-HIAA perchloric acid .

250 μl PRP sample 4 ,

internal standard NMET 200ng vortex mixing , 100
 μl 3.4M perchloric acid vortex mixing ,
 30 4 , 13,000 \times g
 15 4 , 20
 μl HPLC system .
 mobile phase 0.05M sodium acetate, 0.02M citric acid,
 0.5mM sodium octane sulfonic acid, 0.15mMEDTA buffer
 900ml 100ml methanol 1 L , pH 3.2
 glacial acetic acid 0.22 μm pore size filter
 ultra-sonicator 30 degassing . mobile phase
 1 ml/min , Electrochemical detector +800mv vs Ag/AgCl
 electrode potential 0.01 A/s .
 peak retention time 5-HIAA 3.9 , 5-HT 20.0 .
 5-HT internal standard
 peak height 5-HT peak height

Concentration of 5-HT(sample)

= Concentration of 5-HT(standard)

x height of 5-HT(sample)/height of 5-HT(standard)

x height of NMET(standard)/height of NMET(sample)

(3) 5-HT
5-HT .

$$= \frac{\text{PRP 5-HT} - \text{PPP 5-HT}}{\text{PPP 5-HT} \times 10^8} \text{ ng/ml} \div \frac{\text{5-HT}}{\text{5-HT}} / \mu\text{l} \div$$

3.

PRP PPP 5-HT
5-HT , PPP 5-HIAA
paired-Ttest . PRP 5-HT , PPP 5-HT , PPP 5-HIAA
5-HT 가
Pearson's correlation test .
SPSS/PC 0.05 .

1.

31 , 21 .
 1 . ±
 46.57 ±7.40 , 42.87 ±8.48 .
 가 39% 가 61% 가 43%
 가 57% , 70.97%
 90.48% . , , , ,
 , , , .

1.

		(%)	(%)	P (X ² -test)
		12(38.7)	9(42.9)	NS
		19(61.3)	12(57.1)	
()		46.57 ±7.40	42.87 ±8.48	NS (t-test)
		6(19.35)	1(4.76)	NS
		22(70.97)	19(90.48)	
	,	2(6.45)	1(4.76)	
		1(3.23)	0(0.00)	
	6	6(19.36)	2(9.52)	NS
()	7-9	6(19.35)	10(47.62)	
	10-12	14(45.16)	6(28.57)	
	13	5(16.13)	3(14.29)	
		24(79.42)	16(76.19)	NS
		7(22.58)	5(23.81)	

		(%)	(%)	P (χ^2 -test)
		1(3.23)	1(4.76)	
		5(16.12)	2(9.52)	NS
		25(80.65)	18(85.71)	
		10(33.33)	3(14.29)	
		4(13.33)	3(14.29)	NS
		10(33.33)	10(47.62)	
		6(20.00)	5(23.81)	
	50-100	6(20.69)	3(14.29)	
()	100-200	11(37.93)	8(38.10)	
	200-300	3(10.34)	7(33.33)	NS
	300-500	5(17.24)	2(9.52)	
	500	4(13.79)	1(4.76)	
가	가	3(10.71)	1(4.76)	
	가	23(82.14)	18(85.71)	NS
		2(7.14)	1(4.76)	

NS : non-significant

2. SCL-90 HDS

가.

SCL-90 HDS

2

(±) T1

18.29(±9.83), T2가 20.35 (±12.78), T3가 14.55(±7.38), T4가 28.87(±11.44),
T5가 16.35(±8.76), T6가 7.55(±4.05), T7 5.90(±5.74), T8 7.09
(±4.64), T9 12.74(±7.28) SCL-90 131.71(±54.60)

(p<0.001).

HDS

37.16(±9.49)

13.62(±

11.65)

(p<0.001).

.

SCL-90 HDS

2

(±) T1()

9.84(±6.29), T2()가 10.10(±4.13), T3()가 8.10(±4.58), T4()가 14.52(±6.01), T5()가 8.58(±4.97), T6()가 4.45(±2.87), T7() 3.32(±2.70), T8() 4.55(±3.29), T9() 6.19(±4.04) SCL-90 69.65±(31.03) , (p<0.001).

HDS 24.58(±6.18) 37.16(±9.49) (p<0.001).

2. , SCL-90 HDS

	()		()		()	
	N	Mean(SD)	N	Mean(SD)	N	Mean(SD)
SCL-90						
T1	31	18.29(9.83) ^a	31	9.84(6.29) ^b	21	4.43(4.31)
T2	31	20.35(12.78) ^a	31	10.10(4.13) ^b	21	3.33(3.02)
T3	31	14.55(7.38) ^a	31	8.10(4.58) ^b	21	2.62(2.22)
T4	31	28.87(11.44) ^a	31	14.52(6.01) ^b	21	5.48(4.39)
T5	31	16.35(8.76) ^a	31	8.58(4.97) ^b	21	2.71(2.63)
T6	31	7.55(4.05) ^a	31	4.45(2.87) ^b	21	0.95(1.53)
T7	31	5.90(5.74) ^a	31	3.32(2.70) ^b	21	0.57(0.87)
T8	31	7.09(4.64) ^a	31	4.55(3.29) ^b	21	1.19(1.17)
T9	31	12.74(7.28) ^a	31	6.19(4.04) ^b	21	2.43(2.27)
S total	31	131.71(54.60) ^a	31	69.65(31.03) ^b	21	23.71(13.89)
HDS						
H total	31	37.16(9.49) ^a	31	24.58(6.18) ^b	21	13.62(11.65)

a : statistically significantly different between pretreatment depression and control group (p<0.001)

b : statistically significantly different between pretreatment depression and posttreatment depression group (p<0.001)

SCL-90: symptom check list-90

T1 : somatization T2 : obsessive-compulsive T3 : interpersonal sensitivity
T4 : depression T5 : anxiety T6 : hostility

T7 : phobic anxiety T8 : paranoid ideation T9 : psychotism
HDS : Hamilton depression scale

3. PRP 5-HT, PPP 5-HIAA
5-HT

가. 5-HT 5-HIAA
3 PRP 5-HT 97.44 ±
43.72 ng/ml 327.04 ±69.77 ng/ml
(p<0.001), PPP 5-HT 7.57 ±4.01 ng/ml
15.49 ±15.62 ng/ml (p=0.003).
5-HT 1.64 ±0.85 4.86 ±1.72
(p<0.001), PPP 5-HIAA 12.10 ±7.05 17.09 ±12.89
(p=0.041)

. 5-HT 5-HIAA
3 PRP 5-HT 97.44 ±
43.72 ng/ml, PPP 5-HT 7.57 ±4.01 ng/ml, 5-HT
1.64 ±0.85 (
p<0.001). PPP 5-HIAA 12.10 ±7.05 ng/ml
14.08 ±8.39 ng/ml .

. 5-HT 5-HIAA
3 PRP 5-HT
240.93 ±95.17 ng/ml, 5-HT 2.79 ±0.96
(p<0.001). PPP 5-HT 12.20 ±4.26

ng/ml, PPP 5-HIAA 14.08 ±8.39 ng/ml

3. , 5-HT 5-HIAA

	()		()			
	N	Mean(SD)	N	Mean(SD)	N	Mean(SD)
PRP 5-HT	29	97.44(43.72) ^a	29	240.93(95.17) ^d	20	327.04(69.77) ^e
PPP 5-HT	29	7.57(4.01) ^b	29	12.20(4.26) ^d	20	15.49(15.62)
5-HT ratio	29	1.64(0.85) ^a	29	2.79(0.96) ^d	20	4.86(1.72) ^e
PPP 5-HIAA	29	12.10(7.05) ^c	29	14.08(8.39)	20	17.09(12.89)

a : significantly different between pretreatment depression and control group (p<0.001)
 b : significantly different between pretreatment depression and control group (p=0.003)
 c : significantly different between pretreatment depression and control group (p=0.041)
 d : significantly different between pretreatment depression and posttreatment depression group (p<0.001)
 e : significantly different between posttreatment depression and control group (p<0.001)

PRP : platelet rich plasma

PPP : platelet poor plasma

5-HT ratio : intracellular/extracellular 5-HT concentration of platelet

5-HT: 5-hydroxytryptamine

5-HIAA: 5-hydroxyindoleacetic acid

4. 5-HT , 5-HIAA

가. PRP 5-HT SCL-90 HDS

4 PRP 5-HT SCL-90 T1()

T5() (p=0.048, p=0.028), T2(), T8(), T9()
(p=0.004, p=0.003, p=0.004), T3(), T4() (p<0.001)

(p<0.001). SCL-90 T6(), T7(-)
가 . HDS HDS PRP 5-HI
(p=0.002).

. PPP 5-HI SCL-90 HDS
4 PPP 5-HI SCL-90 10
가 (p<0.05), T1 T9
, SCL-90

. HDS HDS .

. 5-HI SCL-90 HDS
4 5-HI SCL-90 25
(p<0.05), T1() ,T2()
T3(), T4(), T8() T9()
(p=0.018, p=0.044, p=0.038, p=0.016, p=0.023,
p=0.022), SCL-90 (p=0.010). HDS
(p<0.001).

. PPP 5-HIAA SCL-90 HDS
4 PPP 5-HIAA T1 T9

SCL-90

. HDS

4. 5-HT

	correlation coefficients(r)			
	PRP 5-HT	PPP 5-HT	5-HT ratio	PPP 5-HIAA
SCL-90				
T1	-0.264*	-0.333	-0.317*	0.106
T2	-0.380**	-0.033	-0.267*	0.032
T3	-0.503***	-0.122	-0.278*	0.162
T4	-0.468***	-0.010	-0.320*	0.020
T5	-0.293*	-0.045	-0.168	0.230
T6	-0.020	0.179	0.010	-0.005
T7	-0.177	0.021	-0.061	0.246
T8	-0.399**	-0.151	-0.307*	-0.015
T9	-0.385**	0.025	-0.307*	0.025
total	-0.447***	-0.084	-0.341**	0.128
HDS				
total	-0.411**	-0.294	-0.438***	0.063

* p < 0.05 ** p < 0.01 *** p < 0.001 by Pearson's correlation test

SCL-90: symptom check list-90

T1 : somatization T2 : obsessive-compulsive T3 : interpersonal sensitivity
 T4 : depression T5 : anxiety T6 : hostility
 T7 : phobic anxiety T8 : paranoid ideation T9 : psychotism

HDS : Hamilton depression scale

5. 5-HT 5-HIAA

가. PRP 5-HT SCL-90 HDS

5 PRP 5-HT SCL-90
. HDS

. PPP 5-HT SCL-90 HDS

5 PPP 5-HT SCL-90
. HDS

. 5-HT SCL-90 HDS

5 5-HT SCL-90

HDS (p=0.043).

. PPP 5-HIAA SCL-90 HDS

5 PPP 5-HIAA SCL-90

. HDS

5. 5-HT

	correlation coefficients(r)			
	Δ PRP 5-HT	Δ PPP 5-HT	Δ 5-HT ratio	Δ PPP 5-HIAA
SCL-90				
Δ T1	0.043	-0.315	0.157	-0.058
Δ T2	0.177	-0.005	-0.134	0.020
Δ T3	0.252	-0.033	0.077	0.048
Δ T4	0.187	-0.097	0.095	0.057
Δ T5	0.238	-0.182	0.167	0.056
Δ T6	0.151	0.094	0.107	-0.140
Δ T7	0.240	0.097	-0.174	0.008
Δ T8	0.188	-0.108	-0.143	-0.098
Δ T9	0.247	-0.135	0.107	-0.008
Δ total	0.252	-0.123	0.151	0.025
HDS				
Δ total	0.120	-0.065	-0.314*	0.235

* $p < 0.05$ by Pearson's correlation test

SCL-90: symptom check list-90

T1 : somatization T2 : obsessive-compulsive T3 : interpersonal sensitivity

T4 : depression T5 : anxiety T6 : hostility

T7 : phobic anxiety T8 : paranoid ideation T9 : psychotism

HDS : Hamilton depression scale

SCL-90

HDS

PRP 5-HT, PPP 5-HT, 5-HT, PPP

5-HIAA 가 . SSRI 4

SCL-90

HDS 가

PRP 5-HT, PPP 5-HT, 5-HT

. PRP 5-HT 5-HT

SCL-90 HDS 가

, - 가 . PPP 5-HT PPP

5-HIAA 가 .

PRP 5-HT, PPP 5-HT, PPP 5-HIAA

SCL-90 HDS

5-HT HDS 가

. PRP 5-HT, PPP 5-HT

5-HT

-

. 5-HT SSRI

가 , SSRI

가 , 5-HT (transporting system)

가 , 가

5-HT 가

5-HT (presynaptic terminal) (synaptic cleft)

5-HT (transporter)

monoamine oxidase 5-HIAA

가

49-57

PRP 5-HT

5-HT

4

4

5-HT 가

PRP 5-HT가

5-HT (degradation) 가,

dense granule

가 가 가

5-HT

가 ⁵⁸⁻⁶⁴ Shaw ⁶⁵

5-HT 5-HT 가

가 ⁶⁶⁻⁶⁸ ^{69, 70}

(active process)

5-HT (passive diffusion)

5-HT 5-HT

V_{max} 가 ³⁰

K_m 가 V_{max}

가 ²⁸ Tuomisto ⁶⁰ Coppen ⁶⁴

5-HT maximum velocity (V_{max}) Michaelis

constant (K_m)

5-HT 5-HT 가

5-HT 5-HT

5-HT 가 5-HT

²⁷

5-HT

SSRI 5-HT 가

가 SSRI 가

SSRI

5-HT

PPP 5-HT

5-HT

PPP 5-HT 가 PRP

5-HT

가

PRP 5-HIAA

5-HT

5-HIAA가

5-HT

5-HT

1.64(±0.85),

4.86(±1.72)

5-HT

5-HT

PRP 5-HT

5-HT

5-HT

5-HT

5-HT

PRP 5-HT 가

SCL-90 HDS

가

SCL-90

HDS

71

5-HT

PRP 5-HT

가

SCL-90-R

HDS

PPP 5-HT SCL-90 HDS
 . PPP 5-HT 가
 . PPP 5-HIAA
 .
 5-HT
 .
 5-HT
 Michaelis (Km)가
 , Km
 가 .²⁸ 5-HT
 (kinetic) 가 .²⁹
 5-HT (density) 가
 HDS (cognitive
 symptom) 가 , 가
 .⁷¹ 5-HT
 (receptor density)
 (cognitive symptom) 5-HT
 가 (vegetative symptom)
 HDS 5-HT 5-HT
 가 .⁷² PRP
 5-HT SCL-90 T1, T2, T3, T4, T5, T8, T9
 T6, T7 . 5-HT
 SCL-90 T1, T2, T3, T4, T8, T9 HDS

, T5, T6, T7

PRP 5-HT 5-HT (somatization),
(obsessive-compulsive), (interpersonal sensitivity),
(depression), (anxiety), (paranoid ideation), (psychotism)

, -

가 5-HT

PPP 5-HT

SCL-90 T1 T9

HDS

PPP 5-HIAA

SCL-90 T1 T9

HDS

PPP 5-HT 5-HIAA 가

PRP 5-HT , PPP 5-HT ,

PPP 5-HIAA SCL-90 HDS

5-HT SCL-90

HDS

5-HT

PRP 5-HT 가

PRP 5-HT 가

PRP 5-HT

SSRI SSRI

5-HT 5-HT 가

(down regulation)

5-HT

SSRI (2

) 4

SSRI

5-HT가 가

SSRI

5-HT 가

SSRI 5-HT 가

5-HT

(active transport), 5-HT ,

(passive diffusion) 5-HT

.⁵⁷ SSRI SSRI가

5-HT

5-HT 가 가

가 .

SSRI PPP 5-HT 7.57ng/ml 12.20 ng/ml

가 SSRI

PRP 5-HT 가

가 가

가가 가

5-HT 가 가

SSRI

5-HT 1.64 ±0.85 2.79 ±0.96 가

SSRI가

5-HT 가

PRP 5-HT 가 5-HT

4

5-HT 가

5-HT ,

SSRI 가 5-HT

가

5-HT 5-HT

가 .

4 ,

5-HI , , ,

4 .

5-HI

5-HI 가 .

, , ,

가 .

31 , 21
 5-HT . 가
 SCL-90 HDS PRP 5-HT , PPP 5-HT
 PPP 5-HIAA HPLC .

1. SCL-90
 HDS ,
 PRP 5-HT , PPP 5-HT , 5-HT , PPP
 5-HIAA .

2. SCL-90
 HDS
 , PRP 5-HT , PPP 5-HT , 5-HT

3. PRP 5-HT 5-HT
 SCL-90 HDS 가
 SCL-90 - 가 .
 PPP 5-HT PPP 5-HIAA
 가 .

4. PRP 5-HT, PPP 5-HT, PPP 5-HIAA
SCL-90 HDS
5-HT HDS
가 .

PRP 5-HT, PPP 5-HT
5-HT
- .
5-HT SSRI
가 5-HT 가
,

1. 3 ; 1995. p.178-98. p.378-99.
2. Kaplan HI, Sadock BJ. Comprehensive textbook of psychiatry. 6th ed. Maryland: Williams & Wilkins; 1995. p.1089-102, p.2024-73.
3. Azmitia EC, Whitaker-Azmitia PM Awakening the sleeping giant. Anatomy and plasticity of the brain serotonergic system J Clin Psychiatry 1991; 52(12 Suppl 1): 4-16.
4. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In; Meltzer HY. editor. Psychopharmacology. The Third Generation of Progress. New York, NY: Raven Press; 1987. p.513-26
5. Peroutka SJ, Sleight AJ, McCarthy BG The clinical utility of pharmacological agents that act at serotonin receptors. J Neuropsychiatry 1989; 1: 253-62.
6. Mss JW Biogenic amines and depression. biochemical and pharmacological separation of two types of depression. Arch Gen Psychiatry 1975; 32: 1357-361.
7. Tanaka M, Kohno Y, Nakagawa R, Nishikawa T, Tsuda A, Nagasaki N Immobilization stress increases serotonin turnover in the extended brain regions in the rat. Kurume Med J 1983; 30: 35-43.
8. Dunn AJ. Changes in plasma and brain tryptophan and brain serotonin and 5-hydroxyindoleacetic acid after footshock stress. Life Sci 1988; 42: 1847-53.
9. Bloom FE, Kupfer DJ. Psychopharmacology. The fourth generation

of progress. New York: Raven Press; 1994. p.933-44.

10. Mes M, Jacob MP, Suy E, Manner B, Leelereg C, Chrisiaens F, Raus J. Suppressant effects of dexamethasone on the availability of plasma L-tryptophan and tyrosine in healthy controls and in depressed patients. *Acta Psychiatr Scand* 1990; 81: 19-23.
11. Mann JJ, Stanley M, Mavride PA, Mewen BS. Increased serotonin and beta-adrenergic receptor binding in the frontal cortexes of suicide victims. *Arch Gen Psychiatry* 1986; 43: 945-59.
12. Mann JJ, Malone KM. Cerebrospinal fluid amines and higher lethality suicide attempts in depressed inpatients. *Biol Psychiatry* 1997; 41: 162-71.
13. Virkkunen M, De Jong J, Bartko J, Goodwin FK, Linnoila M. Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study. *Arch Gen Psychiatry* 1989; 46: 600-3.
14. Virkkunen M, Linnoila M. Brain serotonin type II alcoholism and impulsive violence. *J Stud Alcohol Suppl* 1993; 11: 163-9.
15. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL. Central serotonin activity and aggression, inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. *Am J Psychiatry* 1997; 154: 1430-5.
16. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid, a biochemical suicide predictor? *Arch Gen Psychiatry* 1984; 33: 1193-7.

17. Brown GL, Godwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in humans correlates with cerebrospinal amine metabolites. *Psychiatry Res* 1979; 1: 131-9.
18. Brown GL, Linnoila M. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. *J Clin Psychiatry* 1990; 51: 31-41.
19. Coccaro EF, Kavoussi RJ, Shelton DL, Lish JD, Cernansky JG Impulsive aggression in personality disorder: correlates with ³Hparoxetine binding in the platelet. *Arch Gen Psychiatry* 1996; 53 : 531-6.
20. Stahl SM, Wo DJ, Mdford IN, Berger PA, Garanello RD Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. *AmJ Psychiatry* 1983; 140: 26-30.
21. Roy A, Everett D, Pickar D, Paul SM Platelet tritiated imipramine binding and serotonin uptake in depressed patients and controls. *Arch Gen Psychiatry* 1987; 44: 320-7.
22. Meltzer H, Arora R. Platelet markers of suicidality. In: Mann J, Stanley M editors. *Psychobiology of Suicidal Behavior*. Annals of New York Academy of Sciences. New York: Ann NY Acad Sci; 1986. p.271-80.
23. Meltzer H, Arora R. Platelet serotonin studies in affective disorders. Evidence for a serotonergic abnormality? In: Sandler M, Coppen A, Harnett S, editors. *5-hydroxy-tryptamine in Psychiatry*. New York: Oxford University Press; 1991. p.5-89.
24. Reddy PL, Khanna S, Subbash MN, Cannabasavanna SM, Rao BS. CSF amine metabolism in depression. *Biol Psychiatry* 1992; 31: 112-8.

25. Rickels K, Schweizer E. Clinical review of serotonin reuptake inhibitors. *J Clin Psychiatry* 1990; 51 Suppl B : 9-12.
26. Stahl SM Serotonergic mechanisms and the new antidepressants (editorial). *Psychol Med* 1993; 23: 281-5.
27. Grebb JA. Serotonin-specific reuptake inhibitors. introduction and overview. In: Kaplan HI, Sadock BJ, editors. *Comprehensive textbook of psychiatry*. 6th ed. Baltimore: Williams & Wilkins; 1995. p.2054-6.
28. Asberg M, Traskman L, Thoren P, Bertilsson L, Ringberger VA. Serotonin depression-a biochemical subgroup within the affective disorders? *Science* 1976; 191: 478-80.
29. Baldessarini RJ. Current status of antidepressants. *Clinical pharmacology and therapy*. *J Clin Psychiatry* 1989; 50: 117-26.
30. Schatzberg AF, Dessain E, O'Neil P. Recent studies on selective serotonergic antidepressant. trazodone and fluoxetine. *J Clin Psychopharmacol* 1987; 7: 44S-49S.
31. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. *J Clin Psychopharmacol* 1987; 7: 36S-43S.
32. Stahl SM, Meltzer HY. A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules. comparison with central serotonergic neurons. *J Pharmacol Exp Ther* 1978; 205: 118-32.
33. Kumar AM, Kumar M, Krishnaprasad D, Fernandez JB, Bisdorfer

- C. A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelet and plasma. *Life Sci* 1990; 247: 7151-9.
34. Alfredsson G, Wesel FA. Relationship between clinical effects and monoamine metabolites and amino acids in sulpiride treated schizophrenic patients. *Psychopharmacol* 1990; 101: 324-31.
35. Degrell I, Nagy E. Correlation between cisternal CSF and plasma concentrations of HVA, MHPG, 5-HIAA, DA, and NA. *Biol Psychiatry* 1990; 27: 1179-82.
36. Asberg M, Thoren P, Bertilsson L. Clomipramine treatment of obsessive compulsive disorder. Biochemical and clinical aspects. *Psychopharmacol Bull* 1982; 18: 13-21.
37. Flament M, Rapaport J, Murphy D, Lake C, Berg C. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. *Arch Gen Psychiatry* 1987; 44: 219-25.
38. Leake A, Fairbairn AF, McKeith IG, Ferrier IN. Studies on the serotonin uptake binding sites in depressive disorder and control post-mortem brain. Neurochemical and clinical correlates. *Psychiatry Res* 1991; 39: 155-65.
39. Nash JF, Meltzer HY. Neuroendocrine studies in psychiatric disorder. The role of serotonin. In: Brown SL, van Praag HM editors. *The role of serotonin in psychiatric disorders*. New York: Brunner Mazel; 1991. p.57-9.
40. , , . Haloperidol

Homovanilic Acid 5-Hydroxyindoleacetic

- Acid 1995; 2: 77-90.
41. Fluoxetine
5-HIAA Hamilton Depression Scale .
1996; 3: 269-76.
 42. DSMIV. American Psychiatric Association. Diagnostic and
Statistical Manual of Mental Disorders. 4th ed. Washington. DC:
American Psychiatric Press; 1994.
 43. (SCL-90-R)
(III). 1984; 2: 278.
 44. Hamilton M A rating scale for depression. J Neurol Neurosurg
Psychiatry 1960; 23: 56-62.
 45. Kaplan HI, Sadock BJ. Fluoxetine, Biological therapies, in Synopsis
of Psychiatry. 6th ed. Baltimore: Williams and Wilkins: 1991;
p649-50.
 46. Anderson GM, Feibel FC, Cohen DJ. Determination of serotonin
in whole blood, platelet poor plasma and plasma ultra filtrate.
Life Sci 1987; 40: 1063-70.
 47. Anderson GM, Feibel FC, Wetzlauber LA. Effect of a meal on
human whole blood serotonin. Gastroenterology 1985; 88: 86-9.
 48. Zaczek R, Coyle JT. Rapid and simple method for measuring
biogenic amines and metabolites brain homogenates by HPLC-
electrochemical detection. J Neural Transm 1982; 53: 1-5.

49. Pletscher A. Platelets as models. Use and limitations. *Experientia* 1988; 44: 152-5.
50. Da Prada M, Cesura AM, Launay JM. Platelets as a model for neurones? *Experientia* 1988; 44: 115-26.
51. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by longterm administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. *Neuropsychopharmacol* 1991; 5: 219-29.
52. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortexes of suicide victims. *Lancet* 1983; 214-6.
53. Arora RC, Meltzer HY. Serotonergic measures in the brains of suicide victims. 5-HT binding sites in the frontal cortex of suicide victims and control subjects. *Am J Psychiatry* 1989; 146: 730-6.
54. Yates M, Leake A, Candy JM, Fairbairn AF, Mkeith IG, Ferrier IN. 5-HT receptor changes in major depression. *Biol Psychiatry* 1990; 27: 489-96.
55. Blakely RD, Berson HE. Molecular biology of serotonin receptors and transporters [abstract]. *Clin Neuropharmacol* 1992; 15 Suppl 1: 351A.
56. Sneddon JM. Blood platelets as a model for monoamine containing neurons. *Prog Neurobiol* 1973; 1: 151-98.
57. Pletscher A. Metabolism, Transfer and storage of 5HT in blood platelets. *Br J Pharmacol* 1986; 32: 1-16.

58. Tuomisto J, Tukiainen E. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. *Nature* 1976; 262: 596-8.
59. Coppen A, Swade C, Wood K. Platelet 5-hydroxytryptamine accumulation in depressive illness. *Clin Acta* 1978; 87: 165-8.
60. Tuomisto J, Tukiainen E, Aalfors UG. Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. *Psychopharmacol (Berlin)* 1979; 65: 141-7.
61. Scott M, Reading HW, Loudon JB. Studies on human platelets in affective disorders. *Psychopharmacol* 1979; 60: 131-45.
62. Meltzer HY, Arora RC, Baber R. Serotonin uptake in blood platelets of psychiatric patients. *Arch Gen Psychiatry* 1981; 38: 1322-6.
63. Tuomisto J, Tukiainen E, Aalfors UG. Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. *Psychopharmacol* 1979; 65: 141-7.
64. Coppen A, Rama Rao VA, Swade C. Inhibition of 5-hydroxytryptamine reuptake by amitriptyline and zimelidine and its relationship to their therapeutic action. *Psychopharmacol* 1979; 63: 125-9.
65. Shaw DM, MacSweeney DA, Wokcock N. Uptake and release of 5-hydroxytryptamine by platelets in affective illness. *J Neurol Neurosurg Psychiatry* 1968; 34: 1-16.
66. Delisi LE, Neckers LM, Weinberger DR. Increased whole blood serotonin concentrations in chronic schizophrenic patients. *Arch*

- Gen Psychiatry 1981; 38: 647-50.
67. Freedman DK, Belendiuk K, Belendiuk GW Blood tryptophan metabolism in chronic schizophrenics. Arch Gen Psychiatry 1981; 38: 655-9.
 68. Stahl SM, Garanello RD, Berger PA Platelet serotonin in schizophrenia and depression. a review. In: H. BT, Schoolar JC, Usdn E. editors. Serotonin in Biological Psychiatry. Adv Biochem Psychopharmacol vol 34. New York: Raven Press; 1982.
 69. Jus A, Laskowska D, Zimny S. Recherches sur le comportement de la serotonine dans le serum sanguin des schizophrenes. Ann Med Psychol (Paris) 1958; 116: 898-913.
 70. Feldstein A, Hbagland H, Freeman H. Blood and urinary serotonin and 5-hydroxyindoleacetic acid levels in schizophrenic patients and normal subjects. J Nerv Ment Dis 1959; 129: 62-8.
 71. Rhoades HM, Overall JE. The Hamilton Depression Scale. Factor sorting and profile classification. Psychopharmacol 1983; 19: 91-6.
 72. Apter A, van Praag HM, Plutchik R, Sevy S, Korn M, Brown SL. Interrelationships among anxiety, aggression, impulsivity and mood. A serotonergically linked cluster? Psychiatry Res 1990; 32: 191-9.

Abstract

Relationship between the psychopathology and the concentration of
5-hydroxytryptamine in platelet and plasma of depression.

Mok Hee Park

Department of Medicine

The Graduate School, Yonsei University

(Directed by Professor Sung Kil Min)

There has been accumulating evidences that the abnormalities in CNS serotonergic system are related to depression. However the relationship between the serotonergic abnormalities and psychopathology of depression aren't clarified.

This study is aimed to investigate the relationship between the abnormalities of serotonergic system and the psychopathology in depressive patients.

The subjects were 31 depression patients and 21 healthy adults. Patient group was treated with SSRI for 4 weeks. The psychopathology was assessed by symptom check list-90(SCL-90) and Hamilton depression scale(HDS) and the concentrations of 5-hydroxytryptamine(5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) were measured with high performance liquid chromatography-electrochemical detection(HPLC-ECD). The concentration of 5-HT and 5-HIAA in platelet rich plasma (PRP) and in platelet poor plasma (PPP) and 5-HT ratio between PPP and PRP were compared between depression pretreatment, depression posttreatment and healthy control group. And the psychopathology

of depression measured by SCL-90 and HDS, was correlated with the concentrations of 5-HT and 5-HIAA in PRP and PPP in depression group.

The results were as follows;

- 1) The scores of symptom dimensions and total score of SCL-90 and the total score of HDS of patient group were significantly higher than those of control group and the concentrations of PRP 5-HT, PPP 5-HT and PPP 5-HIAA and 5-HT ratio of patient group were significantly lower than those of control group.
- 2) The scores of SCL-90 and HDS of depression pretreatment group were significantly higher than those of depression posttreatment group. The concentration of PRP 5-HT, PPP 5-HT and 5-HT ratio of depression pretreatment group were significantly lower than those of depression posttreatment group.
- 3) The concentrations of PRP 5-HT and 5-HT ratio in depression pretreatment group were significantly negatively correlated with the score of SCL-90 and HDS, but these are not correlated with dimensions of hostility and phobic-anxiety. The concentration of PPP 5-HT and PPP 5-HIAA were not significantly correlated with the scores of symptom dimension and total score of SCL-90 and HDS score.
- 4) The change of the concentration of PRP 5-HT, PPP 5-HT and PPP 5-HIAA were not significantly correlated with the change of the score of SCL-90 and HDS. The change of the 5-HT ratio was only significantly negatively correlated with the change of HDS score.

These results suggest that abnormalities in serotonin system evidenced by the decreased concentration of PRP 5-HT and PPP 5-HT and 5-HT ratio

are related with depression and that dimensions of hostility and phobic-anxiety were not related with serotonin system. Especially low 5-HT ratio, as it has a significantly relationship with improvement of depression with treatment with SSRI, suggests that the abnormality of 5-HT transport system is related with etiology and improvement of depression.

Key Words : depression, psychopathology, platelet 5-HT